Medical Students' Exposure to and Attitudes About the Pharmaceutical Industry: A Systematic Review

PLoS Medicine

Volumn 8, Issue 5, 2011, Pages

  Austad, Kirsten E ^a,b   Avorn, Jerry ^a   Kesselheim, Aaron S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORRELATION ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT; HUMAN; MEDICAL EDUCATION; MEDICAL STUDENT; PHYSICIAN; PRESCRIPTION; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; STUDENT ATTITUDE; SYSTEMATIC REVIEW; HEALTH PERSONNEL ATTITUDE; MARKETING;

ATTITUDE OF HEALTH PERSONNEL; DRUG INDUSTRY; HUMANS; MARKETING; STUDENTS, MEDICAL;

EID: 79957997098     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001037     Document Type: Review

References (71)

1. Brennan T, Rothman D, Blank L, Blumenthal D, Chimonas SC, et al. (2006) Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295: 429-433.
2. Wilson D, (18 Nov 2009) Medical schools quizzed on ghostwriting. New York Times. Available: http://www.nytimes.com/2009/12/08/health/policy/08grassley.html?scp=11&sq=&st=nyt. Accessed 1 November 2010.
3. Institute of Medicine (2009) Conflict of interest in medical research, education, and practice Washington (D.C.) The National Academies Press.
4. Wazana A, (2000) Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283: 373-380.
5. Lexchin J, Bero L, Djulbegovic B, Clark O, (2003) Pharmaceutical industry sponsorship and research outcome and quality: a systematic review. BMJ 326: 1167-1177.
6. Avorn J, (2004) Powerful medicines: the benefits, risks, and costs of prescription drugs New York Knopf.
7. Avorn J, Choudhry N, (2010) Funding for medical education: maintaining a healthy separation from industry. Circulation 121: 2228-2234.
8. Kesselheim AS, Mello MM, Studdert DM, (2011) Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 8: e1000431 doi:10.1371/journal.pmed.1000431.
9. Landefeld CS, Steinman MA, (2009) The Neurontin legacy-marketing through misinformation and manipulation. N Engl J Med 360: 103-106.
10. Ziegler MG, Lew P, Singer BC, (1995) The accuracy of drug information from pharmaceutical sales representatives. JAMA 273: 1296-1298.
11. Haayer F, (1982) Rational prescribing and sources of information. Social Sci Med 16: 2017-2023.
12. Chren M-M, Landefeld CS, (1994) Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271: 684-689.
13. Manchanda P, Honka E, (2005) The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law & Ethics 5: 785-812.
14. Avorn J, Chen M, Hartley R, (1982) Scientific versus commercial sources of influence on the prescribing behavior of physicians. Amer J Med 73: 4-8.
15. Caudill TS, Johnson MS, Rich EC, McKinney WP, (1996) Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 5: 201-206.
16. Berenson A, (21 Aug 2005) For Merck, Vioxx paper trail won't go away. New York Times. Available: http://www.nytimes.com/2005/08/21/business/21vioxx.html. Accessed 1 November 2010.
17. Korn D, Ehringhaus S, (2007) The scientific basis of influence and reciprocity: a symposium Washington (D.C.) Association of American Medical Colleges.
18. Erlanger HS, Klegon DA, (1978) Socialization effects of professional school. Law & Soc Rev 13: 11-35.
19. Maheux B, Beland F, (1987) Changes in students' sociopolitical attitudes during medical school: socialization or maturation effect? Social Sci Med 24: 619-624.
20. Crandall S, David S, Broeseker A, Hildebrandt C, (2008) A longitudinal comparison of pharmacy and medical students' attitudes toward the medically underserved. Am J Pharm Educ 72: article 148.
21. Papadakis MA, Teherani A, Banach MA, Knettler TR, Rathner SL, et al. (2005) Disciplinary action by medical boards and prior behavior in medical school. N Engl J Med 353: 2673-2682.
22. McCormick B, Tomlinson G, Brill-Edwards P, Detsky A, (2001) Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior. JAMA 286: 1994-1999.
23. AMSA PharmFree Scorecard (2008-2009) (updated 24 August 2010) Reston (Virginia) American Medical Student Association Available: http://www.amsascorecard.org/. Accessed 1 November 2010.
24. University of Pittsburgh Medical Center (12 November 2007) Policy on conflicts of interest and interactions between representatives of certain industries and faculty, staff, and students of the Schools of Health Sciences and personnel employed by UPMC at all domestic locations Pittsburg (Pennsylvania) University of Pittsburgh Available: http://www.coi.pitt.edu/industryrelationships/Policies/IndustryRelationshipsPolicy.pdf. Accessed 1 November 2010.
25. Stanford University School of Medicine (October 2006) (updated 22 July 2010) Policy and guidelines for interactions between the Stanford University School of Medicine, the Stanford Hospital and Clinics, and Lucile Packard Children's Hospital with the pharmaceutical, biotech, medical device, and hospital and research equipment and supplies industries Stanford (California) Stanford University School of Medicine Available: http://med.stanford.edu/coi/siip/policy.html#iv. Accessed 1 November 2010.
26. Stossel T, (2008) Has the hunt for conflicts of interest gone too far? Yes. BMJ 336: 476.
27. Wilson D, (2 March 2009) Harvard Medical School in ethics quandary. New York Times. Available: http://www.nytimes.com/2009/03/03/business/03medschool.html. Accessed 1 November 2010.
28. Glaser B, Bero L, (2005) Attitudes of academic and clinical researchers towards financial ties in research: a systematic review. Science and Engineering Ethics 11: 553-573.
29. Licurse A, Barber E, Joffe S, Gross C, (2010) The impact of disclosing financial ties in research and clinical care: a systematic review. Arch Intern Med 170: 675-682.
30. Sarikaya O, Civaner M, Vatansever K, (2009) Exposure of medical students to pharmaceutical marketing in primary care settings: frequent and influential. Adv in Health Sci Educ 14: 713-724.
31. Fein E, Vermillion M, Uijtdehaag S, (2007) Pre-clinical medical students' exposure to and attitudes toward pharmaceutical industry marketing. Med Educ Online 12 Available: http://www.med-ed-online.net/index.php/meo/article/viewArticle/4465. Accessed 1 November 2010.
32. Ball D, Al-Manea S, (2007) Exposure and attitudes to pharmaceutical promotion among pharmacy and medical students in Kuwait. Pharmacy Education 7: 303-313.
33. Al Khaja K, Handu S, Mathur J, Sequeira R, (2005) Assessing prescription writing skills of pre-clerkship medical students in a problem-based learning curriculum. Int J Clin Pharmacol Ther 43: 429-435.
34. Vinson D, McCandless B, Hosokawa M, (1993) Medical students' attitudes toward pharmaceutical marketing: possibilities for change. Fam Med 25: 31-33.
35. Lea D, Spigset O, Slordal L, (2010) Norwegian medical students' attitudes towards the pharmaceutical industry. Eur J Clin Pharmacol 66: 727-733.
36. Tichelaar J, Richir M, Avis H, Scholten H, Antonini N, et al. (2010) Do medical students copy the drug treatment choices of their teachers or do they think for themselves? Eur J Clin Pharmacol 66: 407-412.
37. Grande D, Frosch D, Perkins A, Kahn B, (2009) Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med 169: 887-893.
38. Markham F, Diamond J, Fayock K, (2009) The effect of a seminar series on third year students' attitudes toward the interactions of drug companies and physicians. The Internet Journal of Family Practice 7 Available: http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijfp/vol7n1/series.xml. Accessed 1 November 2010.
39. Volodina A, Sax S, Anderson S, (2009) Corporate social responsibility in countries with mature and emerging pharmaceutical sectors. Pharmacy Practice 7 Available: http://www.pharmacypractice.org. Accessed 1 November 2010.
40. Tardif L, Bailey B, Bussieres J, Lebel D, Soucy G, (2009) Perceived advantages and disadvantages of using drug samples in a university hospital center: a case study. Ann Pharmacother 43: 57-63.
41. Straand J, Christensen J, (2008) The quality of pharmaceutical consultant visits in general practice. Tidsskr Nor Laegeforen 128: 555-557.
42. Hassali M, Kong D, Stewart K, (2007) A comparison between senior medical students' and pharmacy pre-registrants' knowledge and perceptions of generic medicines. Med Educ 41: 703-710.
43. Sierles F, Brodkey A, Clearly L, McCurdy FA, Mintz M, et al. (2005) Medical students' exposure to and attitudes about drug company interactions. JAMA 294: 1034-1042.
44. Wofford J, Ohl C, (2005) Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes. BMC Med Educ 8: 5-12.
45. Stanley A, Jackson D, Barnett D, (2005) The teaching of drug development to medical students: collaboration between the pharmaceutical industry and medical school. Br J Clin Pharmacol 69: 464-474.
46. Monaghan M, Turner P, Houghton B, Markert RJ, Galt KA, et al. (2003) Pharmacotherapy cost comparison among health professional students. Am J Pharm Educ 67: article 81.
47. Monaghan M, Galt K, Turner P, Houghton BL, Rich EC, et al. (2003) Student understanding of the relationship between the health professions and the pharmaceutical industry. Teach Learn Med 15: 14-20.
48. Wilkes M, Hoffman JR, (2001) An innovative approach to educating medical students about pharmaceutical promotion. Acad Med 75: 1271-1277.
49. Sandberg W, Carlos R, Sandberg E, Roizen M, (1997) The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products. Acad Med 72: 916-918.
50. Hodges B, (1995) Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. Can Med Assoc J 153: 553-559.
51. Weber M, Auger C, Cleroux R, (1986) Knowledge of medical students, pediatric residents, and pediatricians about the cost of some medications. Pediatr Pharmacol (New York) 5: 281-285.
52. Palmisano P, Edelstein J, (1980) Teaching drug promotion abuses to health professional students. J Med Educ 55: 453-454.
53. Vuorenkoski L, Valta M, Helve O, (2008) Effect of legislative changes in drug promotion on medical students: questionnaire survey. Med Educ 42: 1172-1177.
54. Fabbri A, Ardigo M, Grandori L, Reali C, Bodini C, et al. (2008) Conflicts of interest between physicians and the pharmaceutical industry. A quali-quantitative study to assess medical students' attitudes at the University of Bologna. Ricerca Sul Campo 24: 242-254.
55. Fitz M, Homna D, Reddy S, Griffith C, Baker E, et al. (2007) The hidden curriculum: medical students' changing opinions toward the pharmaceutical industry. Acad Med 82: S1-S3.
56. Hyman P, Hochman M, Shaw J, Steinman M, (2007) Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Acad Med 82: 94-99.
57. Vainiomaki M, Helve O, Vuorenkoski L, (2004) A national survey on the effect of pharmaceutical promotion on medical students. Med Teach 26: 630-634.
58. Bellin M, McCarthy S, Drevlow L, Pierach C, (2004) Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school. Acad Med 79: 1041-1045.
59. Barfett J, Lanting B, Lee J, Lee M, Ng V, et al. (2004) Pharmaceutical marketing to medical students: the student perspective. McGill J Med 8: 21-27.
60. Barry D, Cyran E, Anderson R, (2000) Common issues in medical professionalism: room to grow. Amer J Med 108: 136-142.
61. Mantyranta T, Hemminki E, (1994) Medical students and drug promotion. Acad Med 69: 736.
62. Barnes C, Holcenberg J, (1971) Student reactions to pharmaceutical promotion practices. Northwest Med 70: 262-266.
63. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151: W65-W94.
64. Carmody D, Mansfield P, (2010) What do medical students think about pharmaceutical promotion? Australian Med Student J 1: 56-59.
65. American Association of Medical Colleges (26 Oct 2009) 2009 medical school graduation questionnaire: all schools summary report. Available: http://www.aamc.org/data/gq/allschoolsreports/gqfinalreport_2009.pdf. Accessed 1 November 2010.
66. Hafferty F, Franks R, (1994) The hidden curriculum, ethics teaching, and the structure of medical education. Acad Med 69: 861-871.
67. Hafferty F, (1998) Beyond curriculum reform: confronting medicine's hidden curriculum. Acad Med 73: 403-407.
68. Hojat M, Vergare M, Maxwell K, Brainard G, Herrine SK, et al. (2009) The devil is in the third year: a longitudinal study of erosion of empathy in medical school. Acad Med 84: 1182-1191.
69. Woloschuk W, Harasym P, Temple W, (2004) Attitude change during medical school: a cohort study. Medical Education 38: 522-534.
70. Rabinowitz H, (1990) The change in specialty preference by medical students over time: an analysis of students who prefer family medicine. Fam Med 22: 62-63.
71. Higgins J, Thompson S, (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23: 1663-1682.